Australia Needle-Free Injectors Market Size, Share, Growth and Forecast, 2025-2035

Diabetes care and home use shape jet injection demand

The Australia needle-free injectors market was valued at USD 54.5 million in 2025 and is projected to increase from USD 66.0 million in 2026 to USD 144.8 million by 2035, registering a CAGR of 9.13% during 2026–2035. Demand comes from adults and children who inject insulin, growth hormone and other medicines at home, and from clinics that want to avoid needlestick injuries. New South Wales and the Australian Capital Territory held the largest regional share, 33.7% in 2025, because the zone has the largest population and specialist network. Western Australia, South Australia and the Northern Territory form the fastest-growing region at 9.41% a year, as Western Australia adds residents quickly. In turn, pharmacies gained a federal payment for vaccinations in January 2024, which widens professional channels for needle-free delivery.

Which jet injection products does the estimate cover?

The estimate measures the value of needle-free jet injectors sold in Australia, including reusable injector bodies, the consumables these systems use and single-use injection assemblies. It counts purchases by patients, hospitals, specialist clinics and pharmacies through specialist distributors, direct patient sales, pharmacy dispensing and hospital procurement.

The estimate excludes needle-based syringes, pen injectors, autoinjectors, insulin pumps and the medicines that patients inject. The value chain runs from overseas device makers through Australian sponsors and distributors to diabetes educators, endocrinologists, pharmacists and patients.

Consumables lead while single-use assemblies grow fastest

Why do consumables lead product value?

Based on product type, the market is categorized into reusable injector bodies, reusable-system consumables and single-use injection assemblies. Reusable-system Consumables led with a 46.0% share of 2025 value, because each reusable injector needs regular nozzles, adapters and vial connectors. Single-use Injection Assemblies grow fastest at 9.92% a year, as clinics and vaccine users prefer prefilled or disposable formats.

How do home care and pharmacies split use?

Based on care setting, the market is categorized into home care, hospitals, specialist outpatient clinics and community pharmacies. Home Care led with a 52.0% share of 2025 value, because most users inject insulin or hormones themselves every day. Community Pharmacies grow fastest at 10.13% a year, as pharmacists give more vaccinations and train patients on new devices.

Why does diabetes lead disease areas?

Based on disease area, the market is categorized into diabetes, endocrine disorders, vaccine-preventable diseases and specialist treatment indications. Diabetes led with a 58.0% share of 2025 value, because insulin users inject several times a day. Specialist Treatment Indications grow fastest at 9.90% a year, as device makers license jet injectors for other subcutaneous biologic and weight-management therapies.

How fast are powered systems gaining share?

Based on technology, the market is categorized into spring-powered jet systems, pneumatic jet systems and electrically powered jet systems. Spring-powered Jet Systems led with a 74.0% share of 2025 value, because mechanically powered insulin and growth hormone injectors are the main products on sale. Electrically Powered Jet Systems grow fastest at 10.36% a year, as dose control and data recording improve.

Diabetes, patient choice and pharmacy access lift demand

How does recurring diabetes treatment lift device demand?

Recurring diabetes treatment lifts device demand, because people who use insulin inject one or more times every day for life. Diabetes affected 7.4% of Australians aged 20 to 79 in 2024, according to the World Bank. About 1.5 million Australians had diagnosed diabetes and about 500,000 more were undiagnosed, according to the Australian Commission on Safety and Quality in Health Care. Type 1 diabetes reached 117,932 cases in 2025, with 4,207 new cases that year. Diabetes also costs the health system more than $9.1 billion a year. As a result, diabetes holds 58.0% of 2025 value, and jet injectors compete with other diabetes care devices for patient spending.

Why do patient choice and clinical differentiation matter?

Patient-centered delivery and clinical differentiation matter, because some patients avoid or delay injections when they fear needles. The InsuJet injector has been listed on the Australian Register of Therapeutic Goods as a Class IIb device since March 7, 2011, under entry 180917. European Pharma Group named Meditrend International as its Australian distributor for InsuJet version 5 and its consumables from July 2021, according to the Australian Diabetes Educator. The device is described as suitable for all types of insulin. Ferring also lists the ZOMAJET needle-free device for its 10 mg growth hormone product in Australia. In turn, endocrine disorders hold a steady share of value.

Download Free Sample

How do accessible professional channels expand use?

Expansion of accessible professional channels widens use, because pharmacists and nurses can show patients how to use jet injectors at the point of care. The federal National Immunisation Program Vaccinations in Pharmacy program launched on Jan. 1, 2024, paying pharmacies $18.85 for each eligible vaccination. The payment covers people aged 5 and over, while state and territory laws decide which vaccines pharmacists give. PharmaJet's Stratis needle-free system was also chosen in 2020 for an Australian vaccine trial with 150 volunteers at sites in Sydney, Perth and Adelaide. As a result, community pharmacies grow fastest at 10.13% a year.

How do population growth and aging add patients?

Population growth and aging add patients, because older people are more likely to need injected medicines for diabetes and hormone conditions. Australia had 27,921,150 residents at March 31, 2026, after annual growth of 392,700 people, or 1.4%, according to the Australian Bureau of Statistics. Western Australia had the fastest growth rate of any state, at 2.1%, while Tasmania had the slowest, at 0.6%. People aged 65 and over also made up 18.1% of the population in 2025, up from 17.7% in 2024. In turn, the western and central zone grows faster than the national market, as new residents in Perth and regional centers add patients.

Home dosing, consumables and pharmacy vaccines gain ground

How is the shift to needle-free home dosing changing care?

The shift to needle-free home dosing is changing care, because patients who fear needles can inject insulin without a sharp. InsuJet uses a fine liquid jet to send insulin through the skin and is described as suitable for people with needle phobia. About 1.5 million Australians live with diagnosed diabetes, which gives home dosing a large base. NuGen said in July 2023 that InsuJet was approved for sale as a medical device in 42 countries. The company also signed a five-year distribution agreement with SOL-Millennium Medical in July 2023 for Canada, Brazil, France and Spain. As a result, home care holds 52.0% of 2025 value, and Australian patients gain access to devices with wider global support and training material.

Why is the rise of licensed injector brands notable?

The rise of licensed injector brands is notable, because device owners now partner with other companies that sell under their own names. NuGen signed a license, supply and distribution agreement with EziAutoJector on Sept. 27, 2024, and announced it on Oct. 25, 2024. The first purchase order covered 5,000 injectors with consumables, and promotion was planned from January 2025 for long-term weight loss therapy in the United Kingdom and Germany. The device works with U-100 insulin and other subcutaneous biosimilar protein products. In turn, specialist treatment indications grow fastest at 9.90% a year, as jet injectors move into therapies beyond insulin.

Download Free Sample

Can pharmacy vaccination open needle-free volume?

Pharmacy vaccination can open needle-free volume, because pharmacists give large numbers of vaccines each season and value faster, sharps-free delivery. The pharmacy vaccination payment began on Jan. 1, 2024, at $18.85 for each eligible dose for people aged 5 and over. PharmaJet Stratis holds FDA 510(k) clearance, a CE Mark and WHO prequalification certification. Its use in a 150-person Australian vaccine trial at the University of Sydney, the Telethon Kids Institute and the University of Adelaide showed that local researchers already test jet delivery with new vaccines. As a result, vaccine-preventable diseases form a small but growing share, and single-use assemblies grow at 9.92% a year.

Is there room to grow in pediatric endocrine care?

Pediatric endocrine care offers room to grow, because children who need daily insulin or growth hormone often find needles hard to accept. Australia recorded 4,207 new type 1 diabetes cases in 2025, many of them in children and young people. Ferring's ZOMAJET Vision X device is listed for use with its 10 mg growth hormone product, registered as AUST R 156226. Type 1 diabetes prevalence across the Australian population reached 0.44% in 2025. In turn, specialist clinics and diabetes educators can introduce jet injectors early, and suppliers that offer training and child-friendly devices can win long-term users across smart insulin pens and jet systems.

Device cost, limited subsidies and training slow adoption

How do device costs slow adoption?

Device costs slow adoption, because a reusable jet injector costs far more than a box of syringes or pen needles. As a result, many patients stay with needles that national diabetes programs supply at low or no cost. Suppliers respond with trial programs, payment plans and bundled consumables, which help patients compare the full cost over a year of daily injections and see whether fewer missed doses justify the higher upfront price.

Why do limited subsidies hold back demand?

Limited subsidies hold back demand, because public schemes mainly fund needles, syringes and glucose monitoring rather than jet injectors. In turn, most users pay for devices and consumables themselves or through private health insurance. Suppliers respond with clinical data and patient case studies, which support future subsidy applications and help clinicians justify the device for patients with needle phobia, injection site pain or a history of skipped doses.

How does training need limit uptake?

Training needs limit uptake, because patients must learn how to load the device, set the dose and hold it against the skin correctly. As a result, diabetes educators and nurses spend extra time with each new user. Suppliers respond with video guides, educator kits and phone support, which shorten training time and reduce the number of patients who stop using the device during the first few weeks of home treatment.

Why does drug compatibility narrow use?

Drug compatibility narrows use, because each medicine must be tested with a jet injector before clinicians recommend it. In turn, many biologics, vaccines and long-acting drugs remain available only in syringes, pens or autoinjectors. Suppliers respond with partnerships and licensing deals with drug makers, which add approved medicines and widen the range of therapies patients can take without a needle at home or in specialist clinics.

NSW and ACT lead as western and central states grow fastest

Why do new South Wales and the ACT hold the top share?

New South Wales and the Australian Capital Territory held a 33.7% share of 2025 value and grow at 8.91% a year, because the zone had about 9.16 million residents in March 2026. New South Wales alone had about 8.67 million people, the most of any state. Sydney also hosts many endocrinology clinics, diabetes educators and specialist distributors. As a result, the zone leads home care and clinic demand for jet injectors.

How do Victoria and Tasmania support demand?

Victoria and Tasmania held a 24.6% share of 2025 value and grow at 9.01% a year, because Melbourne has a dense network of hospitals and specialist clinics. The zone had about 7.73 million residents in March 2026, including about 580,000 in Tasmania. However, Tasmania had the slowest population growth of any state, at 0.6%. As a result, Victoria drives most growth in the zone through hospital and pharmacy channels.

Download Free Sample

Why are the western and central states growing fastest?

Western Australia, South Australia and the Northern Territory held a 22.7% share of 2025 value and grow fastest at 9.41% a year, because Western Australia had the fastest population growth of any state, at 2.1%, in the year to March 2026. The zone had about 5.28 million residents in total across the three jurisdictions. In turn, Perth and Adelaide add new patients and pharmacy demand each year.

What shapes demand in Queensland?

Queensland held a 19.0% share of 2025 value and grows at 9.31% a year, because the state had about 5.74 million residents in March 2026. Brisbane and south-east Queensland add hospital, pharmacy and home care demand as the population rises.

Download Free Sample

Registration, distribution and program milestones

Spring, gas and electric power define jet delivery

• Spring-powered jet systems store energy in a spring that the user winds before each dose, which keeps the device simple, portable and free of batteries or gas.
• Pneumatic jet systems use compressed gas to drive the dose, which suits clinics and vaccination sessions that give many injections in a row.
• Electrically powered jet systems use a motor to control pressure and dose, which allows more precise delivery and can record each injection for patients and clinicians.

Specialist distributors compete on access and training

Competition is led by a small group of overseas device makers that reach Australian patients through local sponsors and specialist distributors. Meditrend International is the sponsor of the InsuJet entry on the Australian Register of Therapeutic Goods, and European Pharma Group named it Australian distributor for InsuJet version 5 in July 2021. NuGen Medical Devices owns InsuJet and signs licensing and distribution deals, including agreements with SOL-Millennium Medical in 2023 and EziAutoJector in 2024. Ferring supplies its ZOMAJET device with growth hormone in Australia. Rivals compete on ease of use, drug compatibility, training support and consumable costs. Because most users pay for devices themselves, suppliers that work with diabetes educators, pharmacies and endocrinologists win more patients. Distributors also help brands reach hypodermic syringes buyers who want a sharps-free option.

Which companies supply Australian users?

Credence Research view on jet injection uptake

Credence Research's view is that Australian demand for needle-free injectors will grow quickly from a small base because diabetes, hormone therapy and vaccination create daily or seasonal injection needs. Reusable-system consumables remain the largest value pool, while pharmacies and single-use assemblies add the fastest growth. Subsidy decisions will shape how fast patients move away from needles. Suppliers with strong educator networks, pharmacy reach and wider drug compatibility should gain the most, while device costs keep adoption selective.

How the national jet injection estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines diabetes statistics, population data, device registration records, government program information and company announcements. Segment splits and zone growth rates are Credence Research estimates, while zone shares follow the client-defined split. Sources used are official statistics, government publications, professional association publications and company releases, and no interviews or surveys were used.

Home care and pharmacy channels carry growth to 2035

The Australia needle-free injectors market is expected to reach USD 144.8 million by 2035, a 9.13% CAGR during 2026–2035, as more Australians manage diabetes and hormone conditions at home. Growth should be strongest in community pharmacies, single-use assemblies and therapies beyond insulin, because pharmacists give more injections and device makers license new uses. Public subsidy for jet injectors would speed the shift away from needles, while high device costs and training needs could slow it.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.